title: [Behcet's disease therapy review].
abstract: Behçet's disease is an inflammatory process of unknown origin, which usually presents with recurrent oral ulcers, genital aphthae, uveitis and cutaneous lesions. However, a wide variety of clinical manifestations have been reported, and virtually any organ system may be affected, showing central nervous system, joints, blood vessels or gastrointestinal tract involvement. Therapeutic approach remains complex, and varies in basis of the affected organs. Complex aphthosis may respond to topical therapy, colchicine and dapsone. If this therapy does not result in adequate disease control, thalidomide, oral prednisone and methotrexate may be useful. When severe ocular lesions or systemic manifestations are present, therapies tend to be more aggressive, usually combining corticosteroids with immunosuppressive agents as cyclosporin, azathioprine, cyclophosphamide, interferon-alfa-2a, and chlorambucil.
authors.affiliation: Departamento de Medicina Interna, Unidad de Diagnóstico y Seguimiento de Inmunología Clínica y Alergias, Institut Universitari Dexeus, C/Calatrava, 83, 08017 Barcelona.
authors.forename: A
authors.initials: A
authors.lastname: Vidaller Palacín
authors.forename: J
authors.initials: J
authors.lastname: Robert Olalla
authors.forename: B
authors.initials: B
authors.lastname: Sanuy Jiménez
authors.forename: G
authors.initials: G
authors.lastname: Rufi Rigau
authors.forename: J
authors.initials: J
authors.lastname: Folch Civit
authors.forename: A
authors.initials: A
authors.lastname: Charte González
mesh_terms: D001528:Behcet Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D003078:Colchicine / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use
chemical_list: D013792:Thalidomide; D003622:Dapsone; D003078:Colchicine; D011241:Prednisone; D008727:Methotrexate